ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells

ÌÇÐÄ´«Ã½

Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells BRITISH JOURNAL OF HAEMATOLOGY Masir, N., Jones, M., Pozzobon, M., Marafioti, T., Volkova, O. Y., Mechetina, L. V., Hansmann, M. L., Natkunam, Y., Taranin, A. V., Mason, D. Y. 2004; 127 (3): 335-343

Abstract

FCRL (also known as FREB and FcRX) is a recently described member of the family of Fc receptors for immunoglobulin G (IgG). In the present study we analysed its expression in normal and neoplastic lymphoid tissue using immunohistochemical techniques. FCRL was preferentially expressed in a proportion of germinal centre cells and, more weakly, in mantle zone B cells. In addition, strong labelling was observed in marginal zone B cells in the spleen, representing one of the few markers for this cell type. The majority of cases of small B-cell lymphoma, diffuse large B-cell lymphoma and lymphocyte predominance Hodgkin's disease were positive for FCRL. However, the number of positive cells varied widely, and in consequence we could not define a cut-off that distinguished subsets of diffuse large B-cell lymphoma. Our results also showed that FCRL tended to be negative in T-cell-rich B-cell lymphoma and in classical Hodgkin's disease. FCRL may therefore represent a novel marker for normal B cells (e.g. splenic marginal zone cells) and may also be useful as a potential marker of B-cell neoplasms.

View details for

View details for

View details for